A court order that briefly blocked Hospira Inc.'s (HSP) approval to sell a generic version of the Sanofi-Aventis SA (SNY) colon-cancer drug Eloxatin in the U.S. has been dissolved, Hospira said Wednesday.

It added in a filing with the U.S. Securities and Exchange Commission that it has resumed shipments of the drug, known generically as oxaliplatin.

Teva Pharmaceutical Industries Ltd. (TEVA), which also was restrained by Sanofi's legal challenge, said it too resumed shipping oxaliplatin, according to an email from a company spokeswoman.

On Aug. 11, Hospira said it was launching generic oxaliplatin domestically, and that it had one of the first generic versions of the drug in solution form. Hospira noted that the drug racked up about $1.4 billion in U.S. sales for Sanofi last year.

But three days later, Hospira said it received notice from the Food and Drug Administration that the company's oxaliplatin application was suspended due to "legal proceedings initiated by the innovator company against the FDA," and a court order issued in that proceeding.

The court order was dissolved on Tuesday, and Hospira received notice on Wednesday that the previously suspended approved application "has been reinstated by the FDA," the company said in the SEC filing.

"Legal proceedings related to this product are ongoing," Hospira said.

Hospira shares added 2.3% to $39.75, Teva gained 1.3% to $51.45 and Sanofi rose 2.7% to $32.55.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com